CASI Pharmaceuticals, headquartered in Beijing, focuses on developing therapeutics, including the FDA-approved EVOMELA for multiple myeloma, and has a diverse pipeline targeting hematology oncology. The company went public on August 23, 2021, and employs 176 staff.
CASI Pharmaceuticals (CASI) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, CASI Pharmaceuticals's actual EPS was -$0.86, missing the estimate of -$0.48 per share, resulting in a -79.39% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
